News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Andromeda Biotech Announces First Patient Dosed In Extension Study To Its Phase 3 Clinical Trial DIA-AID 2 In Patients With Type 1 Diabetes



12/18/2013 8:20:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

YAVNE, Israel, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. today announces that the first patient was dosed with DiaPep277® for the treatment of type 1 diabetes in its Extension Study to the Phase 3 Clinical Trial DIA-AID 2.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES